Recent Updates
Recently added Catalysts

BGC20-0582

Phase 2

Pediculus Humanus Capitis | Small molecule | Other |Boston Scientific Corporation|Last Updated: Jun 28, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment230
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00528021A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice InfestationPHASE2 COMPLETED 230Aug 1, 2007Jun 1, 2008Jun 28, 20221 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Clinical Cure
Day 15 or 22

Count of participants with No live lice

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORSubjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 2.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
2ACTIVE_COMPARATORSubjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 10% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
3ACTIVE_COMPARATORSubjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 12.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
4PLACEBO_COMPARATOR -
Interventions
NameTypeDescription
PlaceboDRUGVehicle Only
BGC20-0582DRUGBGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
Unlock Study Design Details
Eligibility Criteria
Age Range2 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. The subject and/or his/her parent/legal guardian have provided written informed consent, and, if appropriate, the child has provided assent. 2. Male or female subjects who are between the ages of 2 years (24 months) and 70 years old when consent is signed. 3. Infestation with...

Countries:United States
Unlock Eligibility Criteria